VALNValneva SE

Nasdaq valneva.com


$ 7.82 $ -0.35 (-4.46 %)    

Monday, 24-Jun-2024 15:59:56 EDT
QQQ $ 479.35 $ 5.42 (1.14 %)
DIA $ 391.06 $ -2.96 (-0.75 %)
SPY $ 544.78 $ 2.09 (0.39 %)
TLT $ 94.49 $ 0.16 (0.17 %)
GLD $ 214.55 $ -1.07 (-0.5 %)
$ 7.47
$ 7.82
$ 0.00 x 0
$ 7.63 x 100
$ 7.82 - $ 7.82
$ 6.58 - $ 16.49
17,797
na
-5
$ 2.14
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

Core News & Articles

Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the results of two Phase 2 clinical tria...

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

 valneva-seeks-expanded-use-for-its-chikungunya-vaccine-in-adolescents-with-encouraging-phase-3-data

Valneva released positive Phase 3 data for its single-shot chikungunya virus vaccine in adolescents. The vaccine is also expect...

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

 valneva-reports-further-pivotal-phase-3-data-in-adolescents-for-its-single-shot-chikungunya-vaccine

Results Intended to Support Filing for Potential Label Extension for Use in Adolescents The latest VLA1553-321 data confirmed t...

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

 valneva-for-2024-expects-total-revenues-of-170m-190m-and-rd-investments-between-60m-75m

2024 financial guidance confirmed Expected total revenues between €170 million and €190 million, including: €160 million...

 valneva-q1-revenue-328m-down-from-335m-yoy-net-profit-589m-up-from-net-loss-181m-yoy

Net Profit of €58.9 million, reflecting PRV sale

 valneva-announces-the-initiation-of-phase-1-trial-of-second-generation-zika-vaccine-candidate

The randomized, placebo-controlled, Phase 1 trial, VLA1601-102, is planned to enroll approximately 150 participants aged 18 to ...

 guggenheim-maintains-buy-on-valneva-lowers-price-target-to-17

Guggenheim analyst Evan Wang maintains Valneva (NASDAQ:VALN) with a Buy and lowers the price target from $18 to $17.

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.